Skye Bioscience, Inc.

SKYE

Healthcare|Biotechnology|US

$0.99

-0.05 (-4.78%)

DCF Value

$0.79

Cash / Share

$2.03

Clinical Trials (8)

Trial	Conditions	Phase	Status	Enrollment	Design	Drug
NCT06577090 Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-administered With Semaglutide vs Placebo	Obesity	P2	Active	136	RCT, Double-blind	Nimacimab injection, Nimacimab placebo injection, Nimacimab 300 mg injection
NCT05894265 Prospective Study to Determine the Safety and Effectiveness of a Connective Tissue Allograft Active Matrix (AM) vs. Standard of Care in Arthroscopic Rotator Cuff Repair	Rotator Cuff Tears	N/A	Recruiting	72	RCT, Single-blind	—
NCT06764953 Clinical Trial Evaluating an Amnion Membrane Allograft Intended for Use in the Management of Non- Healing Venous Leg Ulcers Versus Standard Of Care Alone	Venous Leg Ulcers	N/A	Recruiting	100	RCT, Open-label	—
NCT06767501 Clinical Trial Evaluating an Amnion Membrane Allograft for Use in the Management of Non- Healing Diabetic Foot Ulcers Versus Standard Of Care	Diabetic Foot Ulcers (DFUs)	N/A	Recruiting	100	RCT, Open-label	—
NCT05297513 Efficacy of ActiveMatrix on Spinal SSI Rate	Spinal Stenosis Lumbar, Surgical Site Infection	P4	Unknown	275	RCT, Single-blind	ActiveMatrix
NCT05844930 A Study to Determine the Safety and Effectiveness of a Connective Tissue Allograft (ActiveMatrix) Verses Standard of Care in Adhesive Capsulitis of the Shoulder	Adhesive Capsulitis	P4	Completed	56	RCT, Double-blind	Corticosteroid, Lidocaine
NCT06144918 Ph2 Placebo-Controlled Study for Safety & Ocular Efficacy of SBI-100 Ophthalmic Emulsion in Pts w/ Elevated Eye Pressure	Primary Open Angle Glaucoma, Ocular Hypertension	P2	Completed	56	RCT, Double-blind	SBI-100 Ophthalmic Emulsion, 0.5%, SBI-100 Ophthalmic Emulsion, 1.0%, SBI-100 Ophthalmic Emulsion, Placebo
NCT07046000 MRI Evaluation of Graft Maturation Following ACL Reconstruction	ACL Tears		Not Yet Recruiting	10	—	—